

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司
China Resources Pharmaceutical Group Limited
(Incorporated in Hong Kong with limited liability)
(Stock Code: 3320)

VOLUNTARY ANNOUNCEMENT

STRATEGIC COOPERATION WITH HENAN GENUINE BIOTECH

This is a voluntary announcement made by the board of directors (the "**Board**") of China Resources Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**").

STRATEGIC COOPERATION WITH HENAN GENUINE BIOTECH

The Board is pleased to announce that, China Resources Double-Crane Pharmaceutical Co., Ltd. (華潤雙鶴藥業股份有限公司) ("**CR Double-Crane**"), a non-wholly-owned subsidiary indirectly owned as to 59.99% by the Company, has recently entered into a strategic cooperation agreement with Henan Genuine Biotech Co., Ltd. (河南真實生物科技有限公司) ("**Henan Genuine Biotech**") for a term of ten (10) years (the "**Strategic Cooperation Agreement**").

Pursuant to the Strategic Cooperation Agreement, CR Double-Crane and Henan Genuine Biotech will cooperate in various areas and segments, including research and development ("**R&D**"), manufacturing, distribution and other areas directly related to distribution of pharmaceutical products. Specific details of cooperation under the Strategic Cooperation Agreement will be subject to further negotiation between CR Double-Crane and Henan Genuine Biotech based on the actual circumstances of each project.

CR Double-Crane and Henan Genuine Biotech have also entered into a framework agreement for the entrusted manufacturing ("**Entrusted Manufacturing Agreement**"). Henan Genuine Biotech owns the title to Azvudine tablets and has applied for and has been granted with the product registration. It is the license holder for the commercialization with the right to manufacture (whether by its own production or entrusted manufacturing), release and sale of Azvudine tablets. Pursuant to the Entrusted Manufacturing Agreement, Henan Genuine Biotech shall (i) provide CR Double-Crane with technical information, such as the registered prescription, manufacturing process and quality standards of Azvudine tablets, as well as documents required for production and quality control; (ii) guide and inspect the entire manufacturing process undertaken by CR Double-Crane to ensure that all activities of entrusted processing and manufacturing meet the requirements of the relevant pharmaceutical good manufacturing practice (GMP); (iii) decide on rejection and release of the final products; (iv) be responsible for any adverse drug reaction after commercialization; and (v) assume the primary liability for any personal injury caused by product application after commercialization.

CR Double-Crane and Henan Genuine Biotech will further enter into separate agreements for specific matters, such as order plans, settlement, delivery and quality requirements, involved in the entrusted manufacturing based on the actual progress of the clinical trials and approvals for commercialization of the Azvudine tablets. As of the date of this announcement, CR Double-Crane has submitted its application for the C-certificate of Pharmaceutical Production License (藥品生產許可證C證) to the Beijing Municipal Medical Products Administration and the application has been approved.

REASONS FOR AND BENEFITS OF THE STRATEGIC COOPERATION

The signing of the Strategic Cooperation Agreement and the Entrusted Manufacturing Agreement will facilitate their cooperation in various areas and segments, including R&D, manufacturing, distribution and other areas directly related to distribution of pharmaceutical products, thereby enhancing the business development of CR Double-Crane in line with its development need in the future. The Board is of the view that this strategic cooperation with Henan Genuine Biotech is in line with the Group's future development strategies and operational needs and is in the interest of the Company and its Shareholders as a whole.

INFORMATION OF THE PARTIES

The Group's core business encompasses research and development, manufacturing, distribution and retail of an extensive range of pharmaceutical and other healthcare products.

Henan Genuine Biotech is a company established in the People's Republic of China (the "PRC"). It is principally engaged in R&D, manufacturing and distribution of anti-cancer drugs, antiviral drugs, drug treatments for diabetes-related diseases and drug treatments for cardiovascular and cerebrovascular and aging-related diseases; R&D, manufacturing and distribution of medical active pharmaceutical ingredients (APIs), medical tablets, soft and hard capsules, granules, powders and biological preparations; R&D, consulting and services of biomedical technology; R&D, manufacturing and distribution of general chemical products; and acting as an agent for the import, export and sales of various biomedicine (except for commodities and technologies that are restricted by the PRC or prohibited from import and export). For projects which must be approved in accordance with the law, business activities can only be carried out after being approved by the relevant departments.

IMPLICATIONS UNDER THE LISTING RULES

To the best knowledge, information and belief of the directors of the Company, and having made all reasonable enquiries, Henan Genuine Biotech and its ultimate beneficial owner are third parties independent of the Company and its connected persons. Accordingly, the transactions contemplated under the Strategic Cooperation Agreement and the Entrusted Manufacturing Agreements do not constitute a notifiable transaction under Chapter 14 nor a connected transaction under Chapter 14A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

This announcement is made by the Company on a voluntary basis to provide information to its shareholders and potential investors. **Shareholders and potential investors of the Company are reminded to exercise caution in dealing with the securities of the Company.**

For ease of reference, the names of the PRC established companies or entities have been included in this announcement in both the Chinese and English languages, and in the event of any inconsistency, the Chinese versions shall prevail.

By Order of the Board
China Resources Pharmaceutical Group Limited
Han Yuewei
Chairman

Shenzhen, 10 May 2022

As of the date of this announcement, the Board comprises Mr. Han Yuewei as chairman and non-executive Director, Mr. Bai Xiaosong, Mdm. Weng Jingwen and Mr. Tao Ran as executive Directors, Mr. Lin Guolong, Mr. Tan Ying, Mr. Hou Bo and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.